Central Retinal Vein Occlusion Clinical Trial
Official title:
Phase Ib Study on Surgical Stabilizer Assisted Retinal Vein Cannulation (RVC) With tPA Infusion Confirmed by Intraoperative Angio-optical Coherence Tomography (Angio-OCT) for the Treatment of Central Retinal Vein Occlusion (CRVO).
Verified date | March 2023 |
Source | Universitaire Ziekenhuizen KU Leuven |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase Ib study investigates the safety and efficacy of performing a retinal vein cannulation with recombinant tissue Plasminogen Activator infusion into a retinal vein with the help of an updated dedicated surgical stabiliser for the treatment of central retinal vein occlusion.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 10, 2021 |
Est. primary completion date | December 10, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients aged over 18 years - Recent diagnosis (<8 weeks) of CRVO - Recent onset of symptoms (<12 weeks) - Visual acuity < 5/10 in study eye - Visual acuity >1/10 in fellow eye - Central macular thickness >250µm - Signed informed consent prior to inclusion Exclusion Criteria: - Fluorescein allergy - Active neovascularization - Eye disease other than CRVO or Cataract decreasing central vision - History of retinal surgery - High myopia (> -10D) - Contraindication for the use of systemic anticoagulant medication - Extensive macular ischemia noted on fluo-angiography |
Country | Name | City | State |
---|---|---|---|
Belgium | Universitaire Ziekenhuizen Leuven | Leuven |
Lead Sponsor | Collaborator |
---|---|
Universitaire Ziekenhuizen KU Leuven |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Success rate of retinal vein cannulation | successful cannulation defined as peroperatively seen washout of blood in the cannulated retinal vein. The success rate is defined as the number of successful cannulations divided by the total number of cannulation attempts. | 10 min | |
Primary | number of intervention-related surgical complications | These exist of the intra-operative occurence of:
retinal vein tear (visually seen by the surgeon) uncontrollable vitreous cavity hemorrhage (as seen by the surgeon) retinal tear in the proximity of the cannulation site (as seen by the surgeon) intra-/subretinal injection (as seen by the surgeon) breakage of the needle (as seen by the surgeon) failure of stabilizer in holding the instrument immobilized in a certain position (as seen by the surgeon) |
7 days | |
Primary | duration of infusion | The time of infusion measured during surgery with a maximum of 10 minutes | 10 minutes | |
Primary | number of intervention-related non-surgical complications | The postoperative occurence of:
hemorrhagic cerebrovascular accidents due to rtPA (confirmed by CT-scan and neurological examination after referral to the neurologist) large hemorrhage elsewhere to be related with the use of rtPA (as confirmed by clinical examination and/or CT-scan/ultrasound after referral to vascular surgeon) |
7 days | |
Secondary | change in visual acuity after 6 to 8 weeks | best corrected visual acuity tested with ETDRS chart | 6-8 weeks | |
Secondary | change in central macular thickness after 6 to 8 weeks | measurement of central macular thickness with spectral domain-OCT | 6-8 weeks | |
Secondary | intra-/postoperative complications not related to the surgical stabilizer / retinal vein cannulation / rtPA | - complications of intraocular surgery:
wound leak tested with concentrated fluorescein (Seidel effect present/absent) endophthalmitis as seen with the slit lamp/ultrasonography post-operative macular edema objectivated with OCT imaging vitreous hemorrhage > 2 weeks after intervention as seen at the slit lamp and confirmed with ultrasonography development of neovascularization as seen at the slit lamp / fluorescein angiogram |
7 days | |
Secondary | intra-/postoperative complications not related to the surgical stabilizer / retinal vein cannulation / rtPA | - complications during cataract surgery:
iris hemorrhage as seen through the surgical microscope (present/absent) choroidal swelling as seen through the surgical microscope (present/absent) suprachoroidal hemorrhage as seen through the surgical microscope (present/absent) capsule tear as seen through the surgical microscope (present/absent) dropped lens/intraocular lens (IOL). Recombinant tissue Plasminogen Activator (rtPA) as seen through the surgical microscope (occurred/not occurred) |
7 days | |
Secondary | intra-/postoperative complications not related to the surgical stabilizer / retinal vein cannulation / rtPA | - complications during vitrectomy:
retinal tears as seen through the surgical microscope (occurred/not occurred) vitreous hemorrhage as seen through the surgical microscope (occurred/not occurred) choroidal swelling as seen through the surgical microscope (present/absent) suprachoroidal hemorrhage as seen through the surgical microscope (present/absent) |
7 days | |
Secondary | change in retinal flow intraoperatively visualized with OCT-angiography | OCT-angiography visualized flow inside the retinal veins with the intraoperative OCT device; if there is flow the blood vessel is imaged in bright white, if there is no flow the blood vessel is not visible with angio-OCT. | 1 hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT01969708 -
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
|
Phase 3 | |
Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03981549 -
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
|
Phase 1/Phase 2 | |
Completed |
NCT02274259 -
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
|
Phase 4 | |
Completed |
NCT01360385 -
Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
|
N/A | |
Not yet recruiting |
NCT00383773 -
Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion
|
N/A | |
Completed |
NCT00952614 -
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
|
N/A | |
Recruiting |
NCT04601701 -
Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
|
N/A | |
Completed |
NCT01976312 -
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
|
Phase 3 | |
Completed |
NCT01724554 -
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
|
Phase 1/Phase 2 | |
Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01011374 -
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03223714 -
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
|
Phase 3 | |
Recruiting |
NCT01827722 -
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
|
Phase 4 | |
Completed |
NCT00906685 -
Bevacizumab for Central Retinal Vein Occlusion Study
|
Phase 3 | |
Active, not recruiting |
NCT04793100 -
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
|
N/A | |
Recruiting |
NCT02405741 -
Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients
|
Phase 2 | |
Recruiting |
NCT01348633 -
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
|
N/A |